Molecular docking and antihypertensive effects of a novel angiotensin-I converting enzyme inhibitory peptide from yak bone

• DOI: 10.3389/fnut.2022.993744
• Publication Date: 2022-10-12T08:18:08Z
• Authors: Xinchang Gao; Fan Bu; Dalong Yi; Huaigao Liu; Zhiying Hou; Chaoying Zhang; Chang Wang; Jin-Ming Lin; Yali Dang; Yufen Zhao
• Keywords: Captopril; IC50; Docking (animal)

A novel angiotensin-converting enzyme (ACE) inhibitory peptide ser-ala-ser-val-ile-pro-val-ser-ala-val-arg-ala (SASVIPVSAVRA) was purified and identified from yak bone by Electrospray Ionization-Time of Flight-Mass Spectrometry (ESI-TOF-MS). Results in vitro showed that the exhibited strong ACE inhibition activities with an IC 50 54.22 μM. Molecular docking results binding between SASVIPVSAVRA mainly driven van der Waals forces, hydrogen bonds metal receptor. Interestingly, increased about 19% after digestion, but none its metabolites stronger activity than it. The vivo experiment antihypertensive effect at dose 30 mg/kg is nearly equal to Captopril 10 spontaneously hypertensive rats (SHRs). mechanism should be further studied through plasma metabolomics bioanalysis. Structure analysis amino acids peptides produced during digestion may help better understand peptides.